Formulation: 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride, 0.04% polysorbate 20, and 20% glycerol
Purity: ≥90% estimated by SDS-PAGE
Formula Weight: 0
Shelf life (days): 180
Notes: JAK1 is a non-receptor tyrosine kinase that has roles in immune signaling.{62148,19346,54923} It is composed of N-terminal FERM and SH2 domains, a regulatory pseudokinase domain (JH2), and a C-terminal kinase domain.{19346} It is widely expressed and associates with class I and class II cytokine receptors at the plasma membrane.{54923} Activation of these cytokine receptors activates JAK1 and induces its dimerization and kinase activity, leading to JAK1 phosphorylation of STAT transcription factors and transcription of immune-related target genes.{19346,62149} JAK1 signaling is inhibited by the suppressor of cytokine signaling (SOCS) proteins SOCS1, SOCS3, and SOCS5.{54924,62152} Knockout of Jak1 in mice results in perinatal mortality and deficits in lymphopoiesis.{62150} JAK1 fusion proteins and activating mutations in JAK1 are associated with acute myeloid leukemia (AML) and T cell precursor acute lymphoblastic leukemia (ALL).{62151} JAK1 containing a valine-to-phenylalanine substitution (JAK1V617F) in the JH2 domain is associated with disease incidence in patients with polycythemia vera, a thrombotic erythrocyte hyperproliferative disorder. Cayman's JAK1 JH2 domain (human, recombinant; aa 561-852) protein can be used for binding assays and has a calculated molecular weight of 35 kDa.
English
Deutsch
